Literature DB >> 27193456

Mechanisms of MicroRNAs in Atherosclerosis.

Andreas Schober1,2, Christian Weber1,2.   

Abstract

The maladaptation of endothelial cells to disturbed flow at arterial bifurcations increases permeability for lipoproteins. Additional injury by chemically modified lipoproteins disrupts the continuous repair of maladapted endothelial cells and triggers intimal macrophage accumulation. Macrophages remove modified lipoproteins from the extracellular space until the cholesterol overload leads to macrophage death and insufficient efferocytosis. This macrophage failure promotes the progression to advanced lesions by formation of a lipid-rich necrotic core, which may rupture and cause myocardial infarction and stroke. In this article, we summarize the fundamental roles of microRNAs (miRNAs) in the regulation of endothelial maladaptation and macrophage failure during atherosclerosis. We describe how miRNAs coordinate the mutual interaction between chronic endothelial repair and endothelial senescence and mechanistically link the regulation of macrophage cholesterol homeostasis with defective efferocytosis. Lastly, we discuss how miRNAs may challenge and extend current theories about atherosclerosis.

Entities:  

Keywords:  cardiovascular disease; cholesterol; endothelial cell; macrophages; maladaptation; noncoding RNA

Mesh:

Substances:

Year:  2016        PMID: 27193456     DOI: 10.1146/annurev-pathol-012615-044135

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  28 in total

1.  Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.

Authors:  Suowen Xu; Danielle Kamato; Peter J Little; Shinichi Nakagawa; Jaroslav Pelisek; Zheng Gen Jin
Journal:  Pharmacol Ther       Date:  2018-11-13       Impact factor: 12.310

Review 2.  Epigenetic Mechanisms in Monocytes/Macrophages Regulate Inflammation in Cardiometabolic and Vascular Disease.

Authors:  Frank M Davis; Katherine A Gallagher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

3.  Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis.

Authors:  Carrie B Wiese; Jianyong Zhong; Zhi-Qi Xu; Youmin Zhang; Marisol A Ramirez Solano; Wanying Zhu; MacRae F Linton; Quanhu Sheng; Valentina Kon; Kasey C Vickers
Journal:  Atherosclerosis       Date:  2019-01-30       Impact factor: 5.162

4.  Influence of miRNA Gene Polymorphism on Recurrence and Age at Onset of Ischemic Stroke in a Chinese Han Population.

Authors:  Xu Liu; Qianwen Wang; Ruixia Zhu
Journal:  Neurotox Res       Date:  2019-12-06       Impact factor: 3.911

5.  MicroRNA-150 targets ELK1 and modulates the apoptosis induced by ox-LDL in endothelial cells.

Authors:  Bing Qin; Yaqing Shu; Li Xiao; Tingting Lu; Yinyao Lin; Huan Yang; Zhengqi Lu
Journal:  Mol Cell Biochem       Date:  2017-01-21       Impact factor: 3.396

Review 6.  The role of ferroptosis in endothelial cell dysfunction.

Authors:  Wei Yuan; Hao Xia; Yao Xu; Chong Xu; Nan Chen; Chen Shao; Zhiyin Dai; Rui Chen; Aibin Tao
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

Review 7.  Non-coding RNA regulation of endothelial and macrophage functions during atherosclerosis.

Authors:  Binod Aryal; Yajaira Suárez
Journal:  Vascul Pharmacol       Date:  2018-03-15       Impact factor: 5.773

Review 8.  MicroRNAs in endothelial cell homeostasis and vascular disease.

Authors:  Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Curr Opin Hematol       Date:  2018-05       Impact factor: 3.284

Review 9.  Regulatory Non-coding RNAs in Atherosclerosis.

Authors:  Andreas Schober; Saffiyeh Saboor Maleki; Maliheh Nazari-Jahantigh
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Knockdown of circular RNA circMAT2B reduces oxygen-glucose deprivation-induced inflammatory injury in H9c2 cells through up-regulating miR-133.

Authors:  Yanhui Zhu; Chengwei Zou; Yanting Jia; Haizhou Zhang; Xiaochun Ma; Jun Zhang
Journal:  Cell Cycle       Date:  2020-09-08       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.